Article

Sue Friedman on Informed Decision-Making in Hereditary Breast and Ovarian Cancers

Author(s):

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network and the importance of informed decision-making.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers. In this clip, Friedman also stresses the importance of informed decision-making.

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.